Adagene Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Adagene Inc
Access all reports
Adagene Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company utilizes its proprietary technology platforms, including its Dynamic Precision Library (DPL) and SAFEbody technology, to engineer therapeutic antibodies with unique functional epitopes. These technologies enable the development of innovative monoclonal antibodies that target various cancers, aiming to improve both safety and efficacy. Adagene's product pipeline includes several candidates in various stages of clinical and preclinical development. The company is actively engaged in both mono and combination therapies, exploring new approaches to treat solid tumors and other cancer types.The company is headquartered in Suzhou, China, and its shares are listed on the NASDAQ.
Latest articles
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
ADAG
Country
πΊπΈ United States